一分钟看懂
这是一项关于晚期实体瘤的I 期 / II 期研究，登记的药物或干预包括LM-364 for injection；Tislelizumab，当前状态为尚未开始招募。登记地点显示中国北京、新乡、Shiyan、长沙等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
LM-364 for injection；Tislelizumab · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- the first affiliated hospital of Henan medical University · 新乡
- Taihe Hospital Affiliated Hospital of Hubei University of Medicine · Shiyan
- Hunan cancer hospital · 长沙
- Liaocheng People's Hospital · 聊城
- FuDan University Shanghai Cancer Center · 上海
- The First School of Medicine, School of Information and Engineering,The First Affliated Hospital of Wenzhou Medical University · 温州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
- 2. Participants must be ≥18 years or the legal age of consent at the time of signing the ICF.
- 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- 4. Life expectancy ≥ 3 months.
- 5. Adequate organ and bone marrow function as defined by protocol.
- 6. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07847905；登记信息更新于 2026-09-29；本站同步于 2026-10-08。